Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL982388 | 0.78 | KMT2A (0.61) | MEN1KMT2ALMNATHRBBLM | |
| SCHEMBL29786760 | 0.78 | KMT2A (0.61) | MEN1KMT2ALMNATHRBBLM | |
| SCHEMBL27826197 | 0.77 | KDM4E (0.44) | MEN1KMT2ALMNAHTR6KDM4E | |
| SCHEMBL21756096 | 0.77 | KDM4E (0.44) | MEN1KMT2ALMNAHTR6KDM4E | |
| SCHEMBL548147 | 0.75 | LMNA (0.52) | MEN1KMT2ALMNATHRBBLM | |
| Bromide SCHEMBL27826237 | 0.75 | KDM4E (0.43) | MEN1KMT2ALMNAHTR6KDM4E | |
| SCHEMBL4245330 | 0.73 | MEN1 (0.61) | MEN1KMT2ALMNATHRBBLM | |
| SCHEMBL574426 | 0.73 | TDP1 (0.36) | TDP1HTR6L3MBTL1DRD2SLC6A4 | |
| SCHEMBL28379655 | 0.73 | PABPC1 (0.51) | HTR6PABPC1PDK2IDO1ALDH1A1 | |
| SCHEMBL14620684 | 0.71 | MEN1 (0.46) | MEN1KMT2ALMNATHRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102040546-A | Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2011-05-04 | — | — | CN | claimed |
| US-20200062720-A1 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2020-02-27 | — | — | US | disclosed |
| CN-105153056-A | New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylthioalkyl]-methyl acetate | ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD | 2015-12-16 | — | — | CN | disclosed |
| CN-105017168-A | New preparation method of [5-bromo-4-(4-cyclopropyl-naphthalene-1-yl)-4H-[1, 2, 4]triazole-3-ylsulfanyl]-methyl acetate | ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD | 2015-11-04 | — | — | CN | disclosed |
| CN-105017169-A | Preparation method for 4-(4-cyclopropyl-naphthalene-1-yl)-5-thio-[1,2,4]triazolidine-3-ketone and intermediate 4-cyclopropyl-naphthalene-1-yl-ethyl carbamate | ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD | 2015-11-04 | — | — | CN | disclosed |
| CN-104987311-A | Preparing method for (4-(4-cyclopropyl-naphthalene-1-yl)-5-nitr-4H-(1, 2, 4) triazole-3-ylsulfanyl)-ethyl acetate and intermediate (5-nitr-4H-(1, 2, 4) triazole-3-sulfenyl)-ethyl acetate thereof | ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD | 2015-10-21 | — | — | CN | disclosed |
| CN-103524440-B | The preparation method of gout therapertics Lesinurad and Lesinurad intermediate | SUZHOU PENGXU PHARMATECH CO., LTD. (CN) | 2015-09-09 | — | — | CN | disclosed |
| CN-104529848-A | A method for synthesizing 4-(4-cyclopropylnaphthalen-1-yl)-1H-1,2,4-triazole-5(4H)-thione | ANHUI WANBANG MEDICAL TECHNOLOGY CO LTD | 2015-04-22 | — | — | CN | disclosed |
| CN-102040546-B | Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO., LTD. (CN) | 2014-10-15 | — | — | CN | disclosed |
| CN-102040546-B | Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO., LTD. (CN) | 2014-10-15 | — | — | CN | disclosed |
| CN-103524440-A | Preparation method of gout curative medicine Lesinurad and midbody of Lesinurad | SUZHOU PENGXU PHARMATECH CO LTD | 2014-01-22 | — | — | CN | disclosed |
| CN-102040546-A | Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2011-05-04 | — | — | CN | disclosed |
| CN-102040546-A | Preparation method of 4-cyclopropyl-1-naphthaline isothiocyanate and intermediate 4-cyclopropyl-1-naphthaldehyde oxime/halide | TAIZHOU CITY HWASUN PHARMACUETICAL AND CHEMICAL CO LTD | 2011-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062720-A1 | NOVEL PREPARATION METHOD FOR ANTI-GOUT DRUG LESINURAD, AND KEY INTERMEDIATE THEREOF | TXNRD3, TXNRD1, CBR3 | MEN1 4356/4885KMT2A 2161/4885LMNA 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.